Guerbet invests in the Truffle Capital fund dedicated to medical devices and biotechnologies
June 14 2017 - 12:04PM
Villepinte, June
14, 2017 - 6:00 pm CEST - Guerbet (FR0000032526 GBT), a global
specialist in contrast products and solutions for medical imaging,
today announced that it has signed an equity acquisition of fifteen
million Euros in the BioMedTech fund (FPCI) managed by Truffle
Capital which specializes in investing in start-ups developing
technologies and breakthrough products in the life sciences
sector.
The BioMedTech fund which targets
200 million Euros is dedicated to investments in a dozen
essentially French start-ups. They are mostly MedTechs but some are
also BioTechs working in the fields of minimally invasive
interventional medicine (connected prostheses, interventional
imaging, robotics, virtual biopsy, etc.) and biotechnology products
offering breakthrough improvements, particularly in cardiovascular,
osteoarticular, and infectious diseases, or neurology, dermatology,
and oncology.
The Fund's investment criteria,
particularly in the MedTech field are as follows:
-
The development of a radical
innovation, capable of changing the lives of patients;
-
A product capable of becoming a
"first-in-class" or "best-in-class", world leader in its sector in
6-8 years;
-
A very high level management team and
Board of Directors, from the beginning of the activity;
-
A broad and strong intellectual
property portfolio with licensing freedom;
-
Attractive sectors for industrial
acquirers or for stock markets.
Truffle is highly skilled in
detecting radical innovations in American and European universities
and innovative companies with high growth potential. It has
contributed effectively to the structuring and optimization of many
life sciences investments.
"This investment
completes Guerbet's innovation strategy. We want to actively
contribute to the development of new diagnostic or therapeutic
solutions that are very innovative for the health of patients,
particularly those based on minimally invasive, ambulatory or
image-guided procedures. We appreciate Truffle Capital's
entrepreneurial approach and their focus on radical innovations in
medicine," said Yves L'Epine, CEO of Guerbet.
"We are very
pleased Guerbet has so much confidence in us. Our past successes
are based on proven sector-specific expertise, an
entrepreneur-investor strategy, and on our ongoing search in the
world's leading universities for radical innovations to found
start-ups that can change the lives of patients. With our new fund,
we will help build tomorrow's medicine with young companies, many
of which could become global leaders," said Philippe Pouletty,
Managing Director of Truffle Capital.
Guerbet is a pioneer in the
contrast agent field with over 90 years' of experience and is one
of the leaders in medical imaging worldwide. It offers a full range
of pharmaceutical products, medical devices and services for X-ray
(RX) and Magnetic Resonance Imaging (MRI) scanners and
Interventional Radiology and Theranostics (IRT) to improve the
diagnosis and treatment of patients. With 7% of its revenue
dedicated to R&D and more than 200 employees working in its
three centers in France and the United States, Guerbet invests
heavily in research and innovation. Guerbet (GBT) is listed on
Euronext Paris (Segment B - Mid Caps) and generated €776 million in
revenue in 2016. For more information about Guerbet, visit
http://www.guerbet.com
Truffle Capital is an independent
European management company that was founded in 2001 by Philippe
Pouletty MD, Bernard-Louis Roques and Henri Moulard. Today, Truffle
Capital is chaired by Patrick Kron together with its co-founders
Philippe Pouletty and Bernard-Louis Roques, both Managing
Directors. Truffle Capital currently manages over 750 million Euros
through retail funds (FCPI), institutional funds (FPCI), holding
companies and asset management mandates. Truffle is specialized in
the investment and support of companies that are developing
disruptive technologies within two business sectors: the Life
Sciences sector headed by Philippe Pouletty and the Information
Technologies sector headed by Bernard -Louis Roques. For more
information, visit www.truffle.fr
Alize RP
Caroline Carmagnol, Wendy Rigal
truffle@alizerp.com
01 44 54 36 62 / 06 64 18 99 59 |
|
Press release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: GUERBET via Globenewswire
Guerbet (EU:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024